Umbilical vein recanalization with one stage stent placement as modified Meso-rex bypass for portal vein cavernous transformation
10.19538/j.cjps.issn1005-2208.2019.05.20
- Author:
Rui TANG
1
;
Li-han YU
1
;
Li ZHANG
1
;
Qian LU
1
Author Information
1. Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital Beijing 102218, China
- Publication Type:Journal Article
- Keywords:
portal vein cavernous transformation;
portal hypertension;
Meso-rex bypass;
umbilical vein recanalization;
intravascular stent
- From:
Chinese Journal of Practical Surgery
2019;39(05):487-491
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the effect of modified meso-rex surgery combined with umbilical vein recanalization and primary stent implantation in the treatment of portal vein portal vein cavernous transformation.METHODS:A retrospective study was conducted in Beijing Tsinghua Changgung Hospital. A patient underwent classic or thotopic total liver transplantation for more than 9 years, admitted in February 2018 was selected.Her main portal vein occlusion and portal vein cavernous transformation were followed by portal hypertension, esophageal and gastric varices, and gastrointestinal bleeding. Surgical treatment of Meso-rex bypass were performed. During operation, hyperplasia of the left liver was noted. After wedge resection of part of the left liver parenchyma, the stump of ligamentum teres hepatis was exposed. Left portal vein was difficult to be dissected and exposed. After the umbilical vein was recanalized to the left branch of the portal vein, vascular anastomosis and stent implantation were completed. Postoperative anticoagulant therapy was given,and the blood flow was monitored.RESULTS:The shunt procedure was successful. The bypass patent, and blood flow was unobstructed 1-year post-operation. No gastrointestinal bleeding occurred ever.CONCLUSION:Meso-rex bypass combined with umbilical vein recanalization and primary stent implantation can be used to treat patients with portal vein cavernous transformation whose left portal vein is patent but difficult to be exposed.The long-term effect is worth expecting and more cases are needed for further verification.
